Who is eligible to participate?
All patients enrolling in this study should have a diagnosis of moderate Alzheimer's disease and be taking a stable dose of Aricept 10mg daily. Patients should be in good general health.
What is involved in this study?
This study compares 3 doses of the study drug, S38093 to a placebo, in co-administration with 10mg donepezil (Aricept) in patients with moderate Alzheimer's disease. The study drug is an H3 (histamine) receptor antagonist and may slow the progression of the symptoms of Alzheimer's disease.
This study involves a single MRI scan of the brain and as such, patients should be able to tolerate the MRI scanner and have no pacemaker or metal implants which would preclude MRI scanning. No lumbar puncture is required for this study. A carer is required to attend all study visits. Study medication and Aricept will be supplied for the 6 month duration of the study.
This study has the approval of the South Eastern Sydney Local Health District Human Research Ethics Committee.
For more information, please contact Lynne on (02) 9382 3733